Plain-English translation of NCT07536113 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The REalCHALLENGE Study is looking at whether a blood test called ctDNA analysis can help doctors decide which patients with advanced colorectal cancer would benefit from retreatment with anti-EGFR therapy. Researchers will follow patients who have already had this blood test done and track how well their treatment works, aiming to understand whether the blood test results can predict who will respond best to this type of therapy.
Some patients with advanced colorectal cancer stop responding to standard treatments, but doctors currently have limited ways to predict who might benefit from trying anti-EGFR therapy again. This study aims to see whether genetic information found in a simple blood test can help doctors choose the right patients for retreatment, potentially improving outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify, researchers will review your existing medical records and blood test results—you won't need to undergo new treatments or procedures as part of this study. The team will collect information about your cancer diagnosis, your genetic test results, the treatments you received, and how well those treatments worked. They will follow your health outcomes over time to see whether the blood test results accurately predicted your response to treatment.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
Italy
Sponsor
Niguarda Hospital
Enrollment target
~250 participants
Started
March 2024
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Salvatore Siena, MD
ASST Niguarda Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.